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Abstract:  This  paper  presents  an  open-source 
application  for  evaluating  competing  clinical  trial 
(CT)  designs  using  simulations.  The  S4  system  of 
classes and methods is utilized. Using object-oriented 
programming provides extensibility through careful, 
clear interface specification; using R, an open-source 
widely-used  statistical  language,  makes  the 
application extendible by the people who design CTs: 
biostatisticians.  Four  key  classes  define  the 
specifications of the population models, CT designs, 
outcome  models  and  evaluation  criteria.  Five  key 
methods define the interfaces for generating patient 
baseline  characteristics,  stopping  rule,  assigning 
treatment,  generating  patient  outcomes  and 
calculating  the  criteria.  Documentation  of  their 
connections  with  the  user  input  screens,  with  the 
central simulation loop, and with each other faciliates 
the  extensibility.  New  subclasses  and  instances  of 
existing classes meeting these interfaces can integrate 
immediately  into  the  application.  To  illustrate  the 
application,  we  evaluate  the  effect  of  patient 
pharmacokinetic heterogeneity on the performance of 
a common Phase I “3+3” design. 
 
1.  Introduction 
In the past few decades, CT designers have proposed 
hundreds of designs for trials at different stages of 
drug development, ranging from preclinical to Phase 
IV  trials.  This  abundance  of  designs  mandates  a 
question  for  the  investigators  and  statisticians 
planning a trial: what design would be the “best” for 
their trial? Determining the answer must begin with 
careful  consideration  of  the  criterion  by  which  to 
judge designs, which should reflect the goals of the 
trial.  
  CT  simulation  is  used  by  academic  research 
centers and pharmaceutical companies to improve the 
efficiency and informativeness of drug development 
[1-4].  Sophisticated  commercial  software  for  trial 
simulations is available for those  with resources to 
cover fees and with design challenges matching the 
software’s  capabilities.  Academic  research  centers 
usually use locally developed software mainly due to 
cost  and  flexibility  considerations.  Cost  issues  are 
obvious.  Flexibility  is  needed  primarily  to  explore 
novel  designs  and  novel  evaluation  criteria.  This 
local  software  development  focuses  on  answering 
specific  research  questions  in  compressed  time 
frames, and is not routinely sharable. Inspired by the 
success  of  open-source  software  development 
projects, we are building an open-source simulation 
experiment platform with the intention of harnessing 
the power of distributed peer review and transparency 
of process. Techniques in S4 classes and methods [5] 
are utilized to make our package trustworthy, clear 
and extendible. 
In  the  spirit  of  personalized  therapy,  our 
simulation  experiment  platform  acknowledges 
differences among study participants in three aspects. 
The  population  model  for  patients’  baseline 
characteristics may be a mixture model (for example, 
reflecting  pharmacogenetic  heterogeneity).  The 
outcome  model  may  depend  on  patient-specific 
characteristics, and trial designs may allow treatment 
assignments  to  depend  on  measured  or  assayed 
patient baseline characteristics (for example, clinical, 
pathological,  physiologic,  genetic,  or 
pharmacokinetic characteristic).  
Our  vision  for  this  simulation  experiment 
platform is to provide a framework in which new trial 
designs, new models, and new evaluation criteria are 
easily accommodated. The scope of this framework is 
reviewed in the discussion section. In the following 
sections,  we  will  describe  the  framework  and  its 
implementation  using  S4  classes  and  methods  in 
detail, and to illustrate the application, we evaluate 
the  effect  of  patient  pharmacokinetic  heterogeneity 
on  the  performance  of  the  standard  Phase  I  “3+3” 
design  without  dose  de-escalation.  This  example 
introduces  a  new  evaluation  criterion  for  Phase  I 
trials  mapping  from  “recommended  dose”  to  the 
chance of future success in the drug development.  
 
2.  CT Simulation Experiment Framework 
To  begin  a  CT  simulation  experiment,  besides  the 
number  of  simulations  of  a  CT,  the  experimenter 
needs  to  provide  specifications  for  four  major 
components:  population  models,  CT  designs, 
outcome models and evaluation criteria.  
The population model specification contains all the 
necessary  information  to  obtain  the  values  for  a 
participant’s  baseline  characteristics  which  may 
affect either the treatment assignment decision or the 
patient’s outcome. The design specification contains 
all design parameter values for a specific design. The 
outcome  model  specification  provides  the  model 
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generates  each  participant’s  clinical  outcome  based 
on  his/her  baseline  characteristics  and  treatment 
assignments.  The  evaluation  specification  includes 
parameter  values  if  any  for  a  specific  evaluation 
criterion.  
An experiment consists of three loops over the 
population models, designs, and outcome models of 
interest. Within these outermost loops is a loop over 
CT simulations, and within this loop is the loop over 
patients  simulated  for  a  single  CT  simulation.  The 
results are evaluated by the specified criteria at the 
end  of  simulations  under  a  particular  design, 
population model and outcome model. 
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Figure 2.1 Central Simulation Loop 
We display the central simulation loop in Figure 2.1. 
The solid black arrows trace the overall simulation 
flow. The dashed blue   arrows show how the 
specifications are associated with the actions on the  
flow. The dotted red and green arrows show 
exchange of data between  actions  and  the  loop’s 
temporary data repository (which is not intended to 
represent a CT database). As the simulation starts, a 
new patient (or in some cases  n patients as a group) 
enters the CT. The loop generates this new patient’s 
baseline  characteristics  and  then  assigns  treatments 
based  on  the  design,  new  patient’s  baseline 
characteristics, and (if applicable) accumulated data 
from  previous  patients.  A  patient’s  outcomes  are 
generated  from  his/her  baseline  characteristics  and 
treatment  assignments.  After  the  loop  simulates 
outcome  data  for  this  new  patient,  it  applies  the 
stopping  rule  to  decide  whether  to  terminate  the 
simulation  or  continue  the  simulation  by  enrolling 
another new patient. The simulation continues until 
the stopping rule concludes that it must terminate. 
 
3.  Framework Implementation 
3.1  S4 Classes and Methods 
R  is  a  language  and  environment  for  statistical 
computing  and  graphics.  The  R  language  has 
functional-programming  semantics,  whereas  it 
supports  the  object-oriented  programming  (OOP) 
style.  R has two different OOP systems, known as 
S3  and  S4.  Compared  to  S3,  S4  is  more  formal, 
rigorous  and  closer  to  the  “traditional”  OOP  other 
languages like Java and Python follow [5].  The main 
difference between S4 and “traditional” OOP is that 
the method definitions in the S4 system do not reside 
in  a  class  definition  and  methods  sharing  common 
conceptual  properties  and  thus  the  same  name  are 
stored within the generic function according to their 
signature,  a  named  list  of  classes  with  the  names 
corresponding  to  the  formal  arguments  of  the 
function.  With  the  promise  of  making  software 
trustworthy,  clear  and  extendible,  S4  classes  and 
methods  are  highly  encouraged  in  the  R  software 
development [5]. 
   The classes and methods discussed next are the 
ones  participating  in  the  central  simulation  loop  as 
seen in the Figure 2.1, and the ones for evaluation. 
For better illustration, we describe methods under the 
classes  they  are  closely  associated  with.  We 
summarize  the  key  classes  along  with  their 
definitions in the Table 3.1. 
 
3.1.1  Class: “DesignSpecifier” 
“DesignSpecifier”  is  a  class  union  with  member 
classes (a special case of subclasses) representing the 
objects  of  specification  for  a  specific  CT  design. 
These classes contain slots for the design parameters. 
For  example,  a  class  “APlusBNoDeEscSpecifier” 
represents objects of specification for A+B without 
dose de-escalation design described in Lin and Shih’s 
paper  [6],  and  it  contains  slots  for  tier  doses,  the 
initial cohort size (A), the additional cohort size (B) 
and  several  slots  (C,  D,  E)  for  the  dose-limiting 
toxicity  (DLT)  counts  that  are  associated  with 
stopping and dose assignments for the next group of 
patients. 
  Two  methods  are  closely  associated  with  the 
subclasses of “DesignSpecifier”: “applyStoppingRule” 
and  “assignTrt”,  which  both  have  a  subclass  of 
“DesignSpecifier”  and  a  list  representing 
accumulated  CT  data  in  signature. 
“applyStoppingRule”  produces  a  list  with  three 
elements: a Boolean decision on whether to stop the 
trial, conclusions if the trial is to stop and the number 
of additional patients to enroll as a group if the trial is 
to  continue.  The  “assignTrt”  method  has  one 
additional argument corresponding to current patient 
baseline  characteristics  and  this  method  generates 
treatment assignments for the current patient. 
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3.1.2  Class: “BaseCharModelSpecifier” 
“BaseCharModelSpecifier” is a class that represents 
objects  of  model  specification  for  generating  a 
specific  baseline  characteristic.  It  contains  slots  for 
this baseline characteristic name, the names of other 
baseline characteristics which are involved with the 
generation of this baseline characteristic in the model, 
and a string of user-defined R generating function by 
which  we  assume  nothing  about  the  model  for 
generating this baseline characteristic. 
  The  “generateBaseChar”  method  has  two 
arguments  corresponding  to  an  instance  of 
“BaseCharModelSpecifier”  and  a  list  of  values  for 
other baseline characteristics that are involved with 
the  generation.  This  method  generates  a  single 
baseline characteristic for a patient. 
 
3.1.3  Class: “PopModelSpecifier” 
“PopModelSpecifier”  is  a  class  that  represents 
objects of a population model specification. It has a 
slot  to  hold  a  list  of  “BaseCharModelSpecifier” 
objects. 
  The “generateBaseChars” method has only one 
argument  corresponding  to  an  instance  of 
“PopModelSpecifier”.  When  generating  a  new 
selected patient’s baseline characteristics, each of the 
“BaseCharModelSpecifier” objects is utilized by the 
method  “generateBaseChar”  in  turn.  We  facilitate 
expression  of  the  total  joint  distribution  of 
characteristics  by  means  of  sequential  conditional 
distributions. 
 
3.1.4  Class: “OutcomeModelSpecifier” 
“OutcomeModelSpecifier”  is  a  class  union  with 
member classes representing objects of specification 
for a specific outcome  model. The member classes 
contain  slots  for  outcome  model  parameters  if  any 
and one auxiliary slot if otherwise (S4 regards a class 
with no slots as a virtual class and does not allow for 
the instantiation from a virtual class). For example, 
class  “ToxDoseThresholdModelSpecifier”  is  one  of 
the  member  classes  of  “OutcomeModelSpecifier”, 
which  represents  objects  of  specification  for  the 
toxicity  dose  threshold  model.  This  model  can  be 
described using the following equation: 
if 
if 
T
T
Tz
y
tz
   
where  y  denotes  the  outcome,  T denotes  toxicity 
response, t denotes non-toxicity response, z refers to 
dose assignment,  T  is the dose threshold for toxicity 
response  respectively.  No  parameters  are  in  this 
model. 
  The “generateOutcomes” method has arguments 
corresponding  to  an  instance  of  member  class  of 
“OutcomeModelSpecifier”, current patient’s baseline 
characteristics and treatment assignments. It produces 
outcomes for a patient. 
 
3.1.5  Class: “EvalSpecifier” 
“EvalSpecifier” is a class union with member classes 
either directly representing or being the superclasses 
of  the  classes  that  represent  the  objects  of 
specification for a specific evaluation criterion. The 
member classes or subclasses of member classes have 
slots  for  the  evaluation  criterion  parameters  if  any 
and  one  auxiliary  slot  if  otherwise.  For  example, 
“EvalNPatAtTierDose”  class  represents  objects  of 
specification for evaluating the number of patients at 
some tier dose. This class contains one slot for this 
tier dose. 
  The  “evaluateDesign”  method  utilizes 
information from an instance of a member class of 
“EvalSpecifier”, simulated data and conclusions from 
simulated  CT  to  produce  the  result  from  a  single 
evaluation criterion. 
 
Table 3.1 Class Definition 
 
3.2  Interface: requirements and provisions 
Extensibility of our platform requires that a user, with 
a novel design, novel model (population or outcome) 
or  novel  evaluation  criteria  challenge,  can  develop 
new subclasses of the key classes and their associated 
methods, assuring that they will work together. The 
classes and methods described in the previous section 
pass information packets whose exact structure will 
vary in different experiments. We describe below two 
examples that show the “requirements and provisions” 
relationship among classes and methods. 
  Example  1:  The  “applyStoppingRule”  method 
associated with the “APlusBNoDeEscSpecifier” class 
requires  toxicity  outcomes  for  the  last  A  or  A+B 
patients,  experiment  will  be  halted  with  an 
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method fails to provide toxicity outcome. 
  Example  2:  The  “generateOutcomes”  method 
associated  with  “ToxDoseThresholdModelSpecifier” 
class  requires  toxicity  dose  threshold  from  the 
“generateBaseChars” method, error will come out if 
the “generateBaseChars” method fails to provide the 
toxicity dose threshold.  
  Thus,  a  central  component  of  the  open-source 
strategy  is  to  document  these  requirements  and 
provisions for each class and method, to facilitate and 
encourage sharing of innovation. 
 
4.  Example 
4.1  Objective 
In  this  experiment,  we  are  trying  to  evaluate  the 
effect  of  patient  pharmacokinetic  heterogeneity  on 
the performance of the standard Phase I “3+3” design 
without  dose  de-escalation.  We  represent 
pharmacokinetic heterogeneity in terms of bimodality 
of  the  distribution  for  toxicity  dose  threshold.  The 
parameter values in the population model are selected 
only for illustration purposes. 
 
4.2  Experiment Set-up 
Design: Standard Phase I “3+3” design without dose 
de-escalation, with tier doses following the modified 
Fibonacci sequence:  3, 6, 10, 13, 15. 
Population Model 1 (Unimodal): The one baseline 
characteristic produced is a toxicity dose threshold, 
which follows a lognormal distribution whose mean 
is 13, the 4
th dose: 
22 log ~ ( log(13), 0.1 ) T N . 
Population  Model  2  (Mixture):  The  previous 
population  model  1  is  mixed  with  a  small 
subpopulation at much higher risk of toxicity in the 
ratio 0.9 to 0.1. The toxicity dose threshold in this 
subpopulation follows a lognormal distribution:   
22 log ~ ( log(3), 0.1 ) T N  
Outcome  Model:  The  outcome  has  one  Boolean 
component.  Dose-limiting  toxicity  (DLT)  occurs  if 
the dose exceeds the patient’s toxicity threshold.  
Evaluation Criteria:  
  Number of patients enrolled in the CT 
  Number of patients experiencing DLT 
  Probability  of  success  in  Phase  II  trial  at 
recommended  dose  (RD),  where  the  success  is 
defined by concluding that the drug is worthy for 
further studies in the Phase II trial 
The future Phase II trial used to represent a medical 
research beneficial outcome refers to a trial using a 
two-stage  Bryant  and  Day  design  [7],  where  both 
toxicity  and  efficacy  outcomes  are  considered. The 
design  parameters  are  [8]:  for  the  first  stage,  the 
sample  size  is  19  patients,  the  cut-off  values  for 
efficacy  and  non-toxicity  outcomes  are  5  and  11 
respectively; for both stages together, the sample size 
is 33 patients, the cut-off values for efficacy and non-
toxicity  outcomes  are  12  and  22  respectively.  The 
underlying model for dose thresholds for toxicity and 
efficacy responses for Phase II patients are assumed 
to follow bi-lognormal distribution:  
log(13) 1 0.4
(log ,log ) ~ ( , )
log(10) 0.4 4
TE N
We  simulate  1000  replications  of  Phase  I  trials  as 
described above under two scenarios where scenario 
1  uses  unimodal  population  model  and  scenario  2 
uses mixture population model. 
 
4.3  Results 
 
Table 4.1 Number of Patients Enrolled by Scenarios  
 
Table 4.2 Number of Patients Experiencing DLT by 
Scenarios 
 
Table 4.3 RD by Scenarios 
 
Table 4.4 Probability of Success at RD  
The  above  Tables  4.1-4.3  list  the  distribution  of 
number  of  patients  enrolled,  number  of  patients 
experiencing  DLT,  and  RDs  under  two  scenarios 
respectively. RD is set to be zero when lower dose 
than starting dose needs to be claimed as RD.  The 
average  number  of  patients  enrolled  is  13.7  under 
scenario 1, and 14.0 under scenario 2. The average 
number  of  patients  experiencing  DLT  is  2.5  under 
scenario 1, and 2.9 under scenario 2. The addition of 
a  small  subpopulation  of  highly  toxicity  sensitive 
patients  causes  the  Phase  I  trials  to  recommend  a 
lower  dose  more  frequently.  Table  4.4  shows  the 
probability of a successful phase II trial at each RD. 
Given  our  specified  Phase  II  design  and  dose 
thresholds distribution for the patients in the Phase II 
trials,  the  dose  of  6  is  associated  with  the  highest 
probability  of  a  successful  Phase  II  trial.  
Summarizing  across  the  trials,  the  average 
probabilities of success in phase II trial for the two 
scenarios are 13% under scenario 1, and 16% under 
scenario 2. We do not observe any obvious different 
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evaluation  criteria  in  this  example.  Therefore,  this 
example  doesn’t  provide  evidence  that  patient 
pharmacokinetic  heterogeneity  affect  the 
performance  of  the  standard  Phase  I  “3+3”  design 
without dose de-escalation. 
 
5.  Discussion 
The  framework  presented  here  covers  most  CT 
designs. There are some exceptions. Our framework 
cannot cover CTs where treatment assignments may 
occur more than once to a patient, for example, in 
studies with re-randomization of a subset depending 
on intermediate clinical outcomes.  As for the other 
components, there are no obvious limitations beyond 
the willingness of contributors to construct subclasses 
reflecting the models and criteria they prefer.  
  CT  designs  should  consider  both  the  potential 
risks/benefits  for  the  patients  on  the  trial  and  the 
potential scientific/medical value of the knowledge to 
be gained. In our example, we assessed the scientific 
or medical value ( S U ) by the probability of success 
of  a  subsequent  Phase  II  trial  at  the  RD  produced 
from the Phase I trial. Since a Phase I trial is often a 
first-in-human trial, the ethical concerns are critical. 
Operating characteristics which reflect the effects on 
the enrolled patients focus primarily on tabulations of 
adverse events [9, 10]. We could and probably should 
consider  the  balance  among  various  societal  and 
patient  utilities  and  disutilities.  This  simulation 
experiment platform provides a way to do that. For 
example, if the patient has two possible outcomes, T 
(toxicity) and t (non-toxicity), the patient utility can 
be represented by: 
1
()
i
nt
Pi
i h T
U u h  
where  () i uh is  the  utility  for  the  outcome  i h .  Total 
utility  is  measured  by  the  sum  of  patient  utility, 
societal utility and total sampling cost: 
Tot P P S S C C U U U nu  
where  C u is  the  cost  per  patient,  and  the  ’s  are 
multipliers which convert among the different kinds 
of utilities.  
  Commercial simulation platforms for evaluating 
CT  designs  are  out  of  reach  for  many  academic 
centers  conducting  clinical  research.    Academic 
centers  also  have  innovative  CT  methodology 
researchers  facing  an  extremely  varied  array  of 
design  challenges.  To  disseminate  the  innovation, 
expand design capabilities and enhance efficiency, an 
open source solution is urged. 
  Future development of this system will include 
publishing it as an open-source R package, setting up 
an archive site for users to contribute new subclasses 
and corresponding methods (new designs, population 
models,  outcome  models,  and  criteria),  a  user-
friendly  GUI,  user  evaluation  by  CT  designers. 
Complex  factorial  evaluations  will  be 
computationally  time-consuming.  Parallelization  for 
these  demanding  tasks  is  possible,  for  example, 
several  R  packages  provide  support  for  parallel 
processing [11].  
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